May 23, 2017- FDA approves first cancer treatment for any solid tumor with a specific genetic feature
Today, the FDA approved Merck’s Keytruda for microsatellite instability-high (MSI-high) cancers, a tumor type identified by genetic testing. About 4-5% of stomach cancer patients are MSI-high and are now eligible for treatment after at least one prior therapy. This is the first time the FDA has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
View Full Article
Leave a Comment